// STATE LEGISLATION TRACKER

Hawaii HB 872: RELATING TO HEALTH.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Hawaii
Bill: HB 872
Session: 2026
Filed: 2025-01-21
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

HB872 appears to address stock single-use epinephrine access for public schools, businesses, and state or county offices. Based on the title, subjects, and available description, it does not appear to regulate compounded peptides, off-label prescribing, telehealth, clinician scope for peptide care, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No apparent change to peptide access or prescribing
No apparent impact on 503A or 503B compounding
No apparent telehealth prescribing change
Focus is stock epinephrine, not peptides
Peptide clinics likely do not need workflow changes

What to Watch For

Note Watch only if amendments add broader prescription-drug stocking or prescribing rules.

Note The bill may affect emergency medication policies, but not peptide treatment.

Where the Bill Stands

The listed latest action is pending introduction, so the bill does not appear to have advanced in the 2026 process yet.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws